161 filings
Page 2 of 9
8-K
3n56nnn8
8 Aug 23
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
sk24vtrytne18 hdje0
20 Jun 23
Other Events
7:03am
8-K
jsck4
5 Jun 23
Other Events
8:12am
8-K
c7zw5a 2oj7ued87jy70
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
f94qpndv
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
ARS
qnmlocc
18 Apr 23
Annual report to shareholders
4:05pm
DEFA14A
6eh zciusd
18 Apr 23
Additional proxy soliciting materials
4:04pm
S-8
vo2alm7m6gsv
27 Feb 23
Registration of securities for employees
4:08pm
8-K
qktt0dq9fe73 lqr
27 Feb 23
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
4:04pm
8-K
7d6 qt5p2aq
9 Jan 23
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
8:08am
8-K
u6a z8s1s4g
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
8-K
8q6s bf52a57ecqrtmf
20 Oct 22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
4:58pm
424B5
gskjiyrhw
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
pzrea76i5 hulsywbh
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
qe74j8mxxm4 3ww6jf
18 Oct 22
Prospectus supplement for primary offering
5:08pm